Healthcare Industry News: Allergan
News Release - April 4, 2013
Aerie Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific Advisory BoardBEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(Healthcare Sales & Marketing Network)--Aerie Pharmaceuticals, Inc. announced today that Vicente Anido, Jr., Ph.D., was named Chairman of Aerie’s Board of Directors. Dr. Anido is a well-respected ophthalmology industry veteran and leader, who most recently served as President and Chief Executive Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb. Aerie also announced that David Epstein, M.D., Chairman, Department of Ophthalmology, Duke University School of Medicine, and Aerie Co-Founder, has been named as Chairman of the Company’s Scientific Advisory Board.
“On behalf of the Aerie Board and Aerie’s employees, we welcome Vince Anido as our new Chairman, and we look forward to his contributions to Aerie’s continuing success in advancing our novel glaucoma product candidates,” said Thomas van Haarlem, M.D., Aerie’s President and Chief Executive Officer.
From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a Director of ISTA Pharmaceuticals. Prior to this, Dr. Anido was general partner of Windamere Venture partners, served as President and CEO of CombiChem, Inc., a biotechnology company, and was President of the Americas Region of Allergan, a specialty pharmaceutical company focusing on ophthalmology, dermatology and neuromuscular indications. Dr. Anido currently serves on the Board of Directors of QLT, Inc. and Depomed, Inc., both of which are NASDAQ-listed pharmaceutical companies. He received a B.S. in Pharmacy and an M.S. in Pharmacy Administration from West Virginia University, and a Ph.D. in Pharmacy Administration from the University of Missouri-Kansas City.
Dr. Epstein has spent many years addressing the core problem in glaucoma – abnormalities of the trabecular meshwork. He has been honored by a long list of awards throughout his career, and has held several leadership positions in ophthalmology associations, including President of the Association of University Professors of Ophthalmology (AUPO) from 2011 to 2012, President of the Chandler-Grant Glaucoma Society (2004 - 2005), and President of the Association for Research in Vision and Ophthalmology (ARVO) (1992 – 1993), which will be recognizing Dr. Epstein with the Mildred Weisenfeld Award for Excellence in Ophthalmology, to be presented at the 2013 ARVO Annual Meeting in May.
Dr. van Haarlem stated, “David has served as a long-time Aerie Board member and has been a highly valued member of the team since he participated in the Company’s founding in 2005. We are very pleased to have him take this important leadership position heading our Scientific Advisory Board.”
About Aerie Pharmaceuticals
Aerie Pharmaceuticals is a privately held pharmaceutical company in late Phase 2 dedicated to the discovery and development of novel small-molecule treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline of three proprietary products, all of which are well tolerated, high efficacy, once-daily eye drop therapies that include the first new mechanisms of action for glaucoma treatment in nearly 20 years.
The Company’s lead product candidate, AR-12286, is a highly selective Rho Kinase inhibitor that is the first glaucoma therapy to reduce intraocular pressure by relaxing and clearing the trabecular meshwork, which is the eye’s main fluid drain. AR-12286 is expected to be the new, convenient second-line glaucoma drug of choice, in a market where nearly half of patients require second-line or add-on therapy. Aerie’s PG286 fixed combination with travoprost is the first glaucoma therapy to lower intraocular pressure by opening both of the eye’s fluid drains. This new second-line therapy offers the convenience of two drugs in one eye drop and the highest efficacy of any single drop glaucoma medication. The Company’s third product, AR-13324, is a potential first line therapy and the first of a new dual action drug class that reduces the eye’s fluid inflow while also increasing fluid outflow through the trabecular meshwork drain, all in a highly effective single drop per day.
Aerie is located in Bedminster, New Jersey and Research Triangle Park, North Carolina. Further information on the Company is available at www.aeriepharma.com.
Source: Aerie Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.